RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon (FLX475), its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma (HNSCC), at the American Association for Cancer Research (AACR) Annual Meeting which will take place April 5-10, 2024 in San Diego, CA. Late-breaking poster presentation details:
Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PTSession Title:
Phase II Clinical Trials 1Location:
A Combined mregDC and Treg Signature Associates with Antitumor Efficacy of CCR4 Antagonist Tivumecirnon FLX475Abstract Number: Monday, April 8, 2024; 9:00 a.m. - 12:30 p.m. PTSession Title:
Predictive Biomarkers 1Location:
HPK1 inhibits CD8+ T cell effector gene expression following T cell activationAbstract Number: Monday, April 8, 2024; 1:30 - 5:00 p.m. PTSession Title:
Immune Checkpoints and Inhibitory Molecules 2Location:
Poster Section 4 Late-breaking abstract titles are currently available on AACR’s online itinerary planner, and late-breaking abstract text will be available on AACR’s planner on April 5, 2024 at 12:00 p.m. PT. The planner can be accessed at: https://www.abstractsonline.com/pp8/#!/20272.
RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development. areynolds@wheelhouselsa.com
swheeler@wheelhouselsa.com